. 2016 Nov 7;129(2):155–161. doi: 10.1182/blood-2016-09-702324

Table 3.

Current prospective research trials using hydroxyurea therapy for SCA in sub-Saharan Africa

Clinical trial	ClinicalTrials.gov and status	Performance sites	No. of participants	Study end points
Sickle Cell Disease–Stroke Prevention in Nigeria Trial (SPIN)	NCT01801423	Kano, Nigeria	40	TCD velocity
	Active, not recruiting	Kano, Nigeria	40	TCD velocity
Realizing Effectiveness of Hydroxyurea Across Continents (REACH)	NCT01966731	Luanda, Angola; Kinshasa, DRC; Kilifi, Kenya; Mbale Uganda	600	Adherence, toxicity, dosing
	Recruiting	Luanda, Angola; Kinshasa, DRC; Kilifi, Kenya; Mbale Uganda	600	Adherence, toxicity, dosing
Novel use Of Hydroxyurea in an African Region with Malaria (NOHARM)	NCT01976416	Kampala, Uganda	200	Malaria events
	Active, not recruiting	Kampala, Uganda	200	Malaria events
Risk Clinical Stratification of Sickle Cell Disease in Nigeria: Assessment of Efficacy/Safety of Hydroxyurea Treatment	NCT02149537	Ibadan, Nigeria	40	Cytopenia
	Enrolling by invitation	Ibadan, Nigeria	40	Cytopenia
Primary Prevention of Stroke in Children With SCD in Sub-Saharan Africa II (SPRING)	NCT02560935	Kano, Nigeria	440	Stroke occurrence
	Recruiting	Kano, Nigeria	440	Stroke occurrence
Low Dose Hydroxyurea for Secondary Stroke Prevention in Children With Sickle Cell Disease in Sub-Saharan Africa (SPRINT)	NCT02675790	Kano, Nigeria	60	Stroke recurrence
	Not yet recruiting	Kano, Nigeria	60	Stroke recurrence

The ClinicalTrials.gov Web site was last accessed September 29, 2016.